The new Pharmaceutical Policy aims to harmonize regulatory standards, bolster innovation, fortify drug quality and promote indigenization
The government is fostering greater private-public partnering and industry participation
Takeda recently entered a three-year agreement with India's BIRAC to advise and mentor innovators
The government is looking to play a more active role and recover or generate returns via an equity stake or royalty from research projects it finances
The success of the policy will in large part depend on academia-industry linkages working as envisaged
In a major step towards regulatory harmonization, India joined the Pharmacopoeial Discussion Group (PDG) as the first new member in over 30 years

What To Expect From India’s Proposed National Pharmaceutical Policy

Equity Or Royalty For Govt Sought Under R&D Policy